Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Parkinson Disease/drug therapy"'
Publikováno v:
Jensen, P H, Schlossmacher, M G & Stefanis, L 2023, ' Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α-Synuclein ', Movement disorders : official journal of the Movement Disorder Society, vol. 38, no. 3, pp. 378-384 . https://doi.org/10.1002/mds.29318
Two recent, high-profile manuscripts reported negative results with two parallel approaches of passive immunization targeting α-synuclein in a population of patients with early Parkinson's disease (PD). These phase II studies failed to show a bona f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d6de29e0db581cfc074cf3e8a4c7cf5
https://doi.org/10.1002/mds.29318
https://doi.org/10.1002/mds.29318
Autor:
Ullrich Wüllner, Per Borghammer, Chi-un Choe, Ilona Csoti, Björn Falkenburger, Thomas Gasser, Paul Lingor, Peter Riederer
Publikováno v:
Wüllner, U, Borghammer, P, Choe, C-U, Csoti, I, Falkenburger, B, Gasser, T, Lingor, P & Riederer, P 2023, ' The heterogeneity of Parkinson's disease ', Journal of neural transmission (Vienna, Austria : 1996), vol. 130, no. 6, pp. 827-838 . https://doi.org/10.1007/s00702-023-02635-4
Journal of neural transmission 130(6), 827-838 (2023). doi:10.1007/s00702-023-02635-4
Journal of neural transmission 130(6), 827-838 (2023). doi:10.1007/s00702-023-02635-4
The heterogeneity of Parkinson’s disease (PD), i.e. the various clinical phenotypes, pathological findings, genetic predispositions and probably also the various implicated pathophysiological pathways pose a major challenge for future research proj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b19787179daf693469a3fce56cf597
https://pure.au.dk/portal/da/publications/the-heterogeneity-of-parkinsons-disease(2c2a9eb1-19a4-4783-bf97-902f68603c22).html
https://pure.au.dk/portal/da/publications/the-heterogeneity-of-parkinsons-disease(2c2a9eb1-19a4-4783-bf97-902f68603c22).html
Autor:
Günter Höglinger, Claudia Schulte, Wolfgang H. Jost, Alexander Storch, Dirk Woitalla, Rejko Krüger, Björn Falkenburger, Kathrin Brockmann
Publikováno v:
Journal of neural transmission 129(9), 1219-1233 (2022). doi:10.1007/s00702-022-02511-7
Given the clear role of GBA in the pathogenesis of Parkinson’s disease (PD) and its impact on phenotypical characteristics, this review provides an overview of the current knowledge of GBA-associated PD with a special focus on clinical trajectories
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e08d3c9aa141e5f955f24c955360bf43
https://doi.org/10.1007/s00702-022-02511-7
https://doi.org/10.1007/s00702-022-02511-7
Publikováno v:
Journal of Neural Transmission. 129:773-804
The novel antibiotic-exploiting strategy in the treatment of Alzheimer's (AD) and Parkinson's (PD) disease has emerged as a potential breakthrough in the field. The research in animal AD/PD models provided evidence on the antiamyloidogenic, anti- inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30f8896fb3277f958a9e9d458d2bed5f
https://doi.org/10.1007/s00702-021-02457-2
https://doi.org/10.1007/s00702-021-02457-2
Autor:
Chanawat Anan, Roongroj Bhidayasiri, Teus van Laar, K. Ray Chaudhuri, Aukkritthiwat Phimpha, Onanong Phokaewvarangkul
Publikováno v:
Parkinsonism & Related Disorders, 91, 146-151. Elsevier
INTRODUCTION: Although continuous subcutaneous apomorphine infusion (CSAI) is an effective therapy for Parkinson's disease (PD) with motor fluctuations, data from Asian cohorts is limited. The therapy is often discontinued due to the complexity of it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec26741522ac43aad3e98e57154c2948
https://doi.org/10.1016/j.parkreldis.2021.09.022
https://doi.org/10.1016/j.parkreldis.2021.09.022
Autor:
Ruxandra Julia Vorovenci, Mihaela Simu, Cristina Bejinar, Inge Krabbendam, Amalia M. Dolga, Ioan Ovidiu Sirbu, Cristina Dijmarescu, Cecilia Rosca, Aimee Rodica Chis, Catalin Marian, Alexandra Ioana Moatar
Publikováno v:
Journal of Cellular and Molecular Medicine
Journal of cellular and molecular medicine, 25(18), 8715-8724. Wiley
Journal of cellular and molecular medicine, 25(18), 8715-8724. Wiley
Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::422f4bd45a01e02203e07b405af972db
https://doi.org/10.1111/jcmm.16827
https://doi.org/10.1111/jcmm.16827
Autor:
Tove Henriksen, Olivier Rascol, Regina Katzenschlager, Andrew J. Lees, Guenther Deuschl, Teus van Laar, Claudia Trenkwalder, Donna Lockhart, K. Ray Chaudhuri, Werner Poewe, Harry Staines
Publikováno v:
Parkinsonism & Related Disorders, 83, 79-85. Elsevier
Introduction: The randomized, double-blind phase (DBP) of the TOLEDO study confirmed the efficacy of apomorphine infusion (APO) in reducing OFF time in PD patients with persistent motor fluctuations despite optimized oral/transdermal therapy. Here we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e87696072989fe422ae56aa359012a60
https://doi.org/10.1016/j.parkreldis.2020.12.024
https://doi.org/10.1016/j.parkreldis.2020.12.024
Autor:
Harmen R Moes, Gerrit Tissingh, Teus van Laar, Martje Drent, Jerney W M J Groenendal-Laurensse
Publikováno v:
Journal of Parkinson's Disease
Journal of Parkinson's Disease, 10(3), 935-944. IOS Press
Journal of Parkinson's Disease, 10(3), 935-944. IOS Press
Background: Continuous intra-duodenal infusion of levodopa-carbidopa intestinal gel (LCIG) is a well-established therapy for patients with advanced Parkinson's disease (PD) suffering from motor complications despite optimized treatment with oral dopa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d404bca40fda3c06518765a15f7b758b
https://research.rug.nl/en/publications/42170245-856f-4b79-bc6e-9d0a367a5133
https://research.rug.nl/en/publications/42170245-856f-4b79-bc6e-9d0a367a5133
Publikováno v:
Expert review of neurotherapeutics. 20(6):523-537
INTRODUCTION: The increasing global burden of Parkinson's disease (PD) poses a particular challenge for developing countries, such as Thailand, when delivering care to a geographically diverse populace with limited resources, often compounded by a la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___01423::e86d437072c7d0596a3297d61915a787
https://research.rug.nl/en/publications/b42e3582-0838-4241-8990-a6a5cc303670
https://research.rug.nl/en/publications/b42e3582-0838-4241-8990-a6a5cc303670
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease
Publikováno v:
Mori, A, Chen, J-F, Uchida, S, Durlach, C, King, S M & Jenner, P 2022, ' The Pharmacological Potential of Adenosine A 2A Receptor Antagonists for Treating Parkinson's Disease ', Molecules (Basel, Switzerland), vol. 27, no. 7, 2366 . https://doi.org/10.3390/molecules27072366
The adenosine A2A receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson’s disease (PD). The selective A2A receptor antagonist istradefylline is approved in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc23bf57ffde6939325349c3cc803226
https://doi.org/10.3390/molecules27072366
https://doi.org/10.3390/molecules27072366